Issuu on Google+

Consolidated Investment Analysis for Adventrx Pharmaceuticals, Inc.

Adventrx Pharmaceuticals, Inc (AMEX:ANX)

Company Description Adventrx Pharmaceuticals, Inc (AMEX:ANX) was incorporated in 1995 and is engaged in development, manufacturing and marketing of products candidates used for treatment of cancer. The company’s product portfolio includes ANX-530 and ANX-514. ANX-530 is a renowned emulsion formulation which is used for treatment of advanced non small cell lung cancer. ANX-530 works as a single agent or in combination with cisplatin. ANX-514 is an emulsion formulation derived from chemotherapy drug docetaxel which is used for the treatment of breast and non small cell lung cancer. Head quartered in San Diego, California the company’s products are used for non small lung cancer, breast cancer, prostate cancer, gastric cancer, head cancer and neck cancer.

Share Statistics Symbol Current Price 52 week range Avg Volume

ANX $2.88 1.50 - 13.00 484,139.00

EPS: Market Capitalization: 52 week change Beta

-2.00 41.60M 766% 0.85

Financial Summary As per its financial statements ending September 30th, 2010 the company has not realized any revenues yet as it is in the development stage. The company’s total operating expenses stand at $1.87 million for the quarter ending September 30th, 2010. The total operating expenses have been reduced by almost 4 percent to $1.87 million for the respective quarter as compared to operating expenses of $1.94 million for the quarter ended June 30th, 2010. The company’s total assets accumulate up to $30.49 million according to its balance sheet as on September 30th, 2010. Current assets happen to have the highest proportion in the composition of total assets standing at $30.46 million. The company maintains a strong short-term liquidity position with current ratio of 17.935 times which shows that Adventrx maintains current assets 18 times more than its current liabilities. The company’s high short term liquidity position is also evident from the fact that its cash and cash equivalent standing at $29.33 million covers current liabilities by 17 times.


Latest Updates Adventrx Pharmaceuticals, Inc (AMEX:ANX) announced its submission of request for discussion on its product candidate ANX-514 to US Food and Drug Administration FDA as on December 15th, 2010. The FDA will set the date of meeting for discussion within 60 days of request application. The company’s product candidate ANX-514 is branded as Taxotere which has been extensively scrutinized by the company and is ready to be launched in the market. Moreover the company entered into an agreement with New Island Resources Inc on December 10th, 2010 for the acquisition of Pine Cove mine and mill which is held by New Island Resources.

Technical Analysis Chart


Disclaimer: DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE OR IN ONE OF OUR NEWSLETTERS. We are not registered as a securities brokerdealer or an investment advisor either within the U.S. Securities and Exchange Commission (the “SEC�) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.

The information contained on our website or in any of our newsletters should be viewed as commercial advertisement and is not intended to be investment advice. Any information found on our website, or in any of our newsletters is not provided to any particular individual with a view toward their individual circumstances. The information contained on our website, and in any newsletter we distribute, is not an offer to buy or sell securities. We distribute opinions, comments, and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained on our website or in one of our newsletters about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment adviser or licensed stock broker before investing.

This website is a service of Seo Freisin, Inc., a financial public relations firm that has been compensated by the companies profiled. All direct and third party compensation received has been disclosed on both, this newsletter, and on our website in accordance with section 17(b) of the Securities Act of 1933. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies.

Seo Freisin, Inc., and/or its affiliates will hold, buy, and sell securities in the companies profiled. When compensated in shares, all readers should be aware that it is our policy to liquidate all shares immediately. We reserve the right to buy or sell the shares of any the companies mentioned in any materials we produce at any time. This compensation constitues a conflict of


interest as to our ability to remain objective in our communication regarding the profiled companies.

Information contained in our report will contain “forward looking statements” as defined under section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance asto the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and thereforecannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in this report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).


Adventrx Pharmaceuticals, Inc (AMEX: ANX)